Aspirin for primary prevention of cardiovascular disease

Affiliations

¹ Division of Cardiology, AOU "Policlinico Vittorio Emanuele", PO Rodolico, Catania 95123, Sicily, Italy. Electronic address: dcapodanno@gmail.com.
² Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

Comment

Davide Capodanno et al. Lancet. 2018.

. 2018 Sep 22;392(10152):988-990.

doi: 10.1016/S0140-6736(18)31990-1. Epub 2018 Aug 26.

¹ Division of Cardiology, AOU "Policlinico Vittorio Emanuele", PO Rodolico, Catania 95123, Sicily, Italy. Electronic address: dcapodanno@gmail.com.
² Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

No abstract available

Comment on

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G; ARRIVE Executive Committee. Gaziano JM, et al. Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26. Lancet. 2018. PMID: 30158069 Free PMC article. Clinical Trial.